Natural Memory Support
Faster Learning. Enhanced Memory. Improved Mental Performance.
Synapsa™ Natural Memory Support is a patented, standardized form of Bacopa monnieri that has been the subject of more than 30 years of clinical study. While most cognitive health supplements focus on the issue of cognitive decline – mainly in an aging population - the studies behind Synapsa focus on ‘peak cognitive performance’ outcomes that offer benefits for a much broader public. In six double-blind, placebo-controlled clinical studies, healthy adults using Synapsa showed significantly improved performance in areas such as visual processing, learning rate, working memory, information retention and mental performance in cognitively demanding environments versus a placebo regimen.
Two types of use supported by studies
Studies show support for two distinct types of benefit from Synapsa Natural Memory Support: daily, long-term use (chronic) to enhance learning and memory, and short-term use (acute) to improve mental performance in cognitively demanding environments such as test-taking. In addition, the majority of studies behind Synapsa have been conducted on healthy adult subjects between 18-65. From a market standpoint, in the United States today, more than 120 million people are considered knowledge workers who use cognitive skills as a daily part of their jobs. In addition, recent estimates of college students range upwards of 21 million. Both groups are good targets for new formulations based on Synapsa, along with any consumers looking for support for learning, memory and mental performance.
A foundation for your cognitive health products
With a large, engaged target demographic and solid clinical support, Synapsa can be effective in both single- and multi-ingredient formulations within your cognitive health platform.
For more information, visit the Synapsa website at www.synapsa.info
The above statements are intended as suggestions only. Use of claims on product labeling and marketing materials should be vetted and approved by your regulatory and legal departments.
Relevant Studies for the 'Peak Performance' Demographic
The patented, standardized Synapsa extract has been the focus of seven ‘foundational’ clinical trials and six ‘targeted’ clinical trials over the last thirty years. The most intriguing studies include:
Stough, 2001 showed a statistically significant improvement in speed of visual information processing, learning rate and memory consolidation in subjects 18-60 years of age consuming 300 mg/day Synapsa. A statistically significant reduction in the rate of forgetting was also observed.
Roodenrys, 2002 conducted a randomized, double-blind, placebo-controlled 12-week trial that demonstrated a significant effect of Synapsa (300mg/d) on the retention of new information by participants 40-65 years of age.
Stough, 2008 conducted a randomized double-blind, placebo-controlled 90-day study with 62 participants, ages 18-60, consuming 300 mg/day. Synapsa showed a statistically significant improvement in working memory, visual information processing (sustained attention) and accuracy in complex cognitive tasks.
Downey, 2012 studied two different doses (320 mg/640 mg) in a study on sustained cognitive performance, examining the acute (short term) effect of Synapsa in healthy adult subjects. Significantly improved performance was seen in faster information processing and improved decision making time in a multitasking environment.
P.L. Thomas is committed to an on-going program of clinical study for Synapsa – with more support for the target market, as well as new indications. Additional information on these studies and more are available from P.L. Thomas.
Stough et al. The chronic effects of an extract of Bacopa monniera on cognitive function in healthy human subjects, Psychopharmacology, 2001
Roodenrys et al. Chronic effects of Brahami on human memory, Neuropsychopharmacology, 2002
Stough et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning, Phytotherapy Research, 2008; 22:1629-1634.
Downey et al. An Acute, Double-Blind, Placebo-Controlled Crossover Study of 320 mg and 640 mg Doses of a Special Extract of Bacopa monnieri (CDRI 08) on Sustained Cognitive Performance. Phytother Res 2012